A citation-based method for searching scientific literature

Laween Uthman, Marius Kuschma, Gregor Römer, Marleen Boomsma, Jens Kessler, Jeroen Hermanides, Markus W Hollmann, Benedikt Preckel, Coert J Zuurbier, Nina C Weber. Cardiovasc Drugs Ther 2021
Times Cited: 13







List of co-cited articles
136 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
Bernard Zinman, Christoph Wanner, John M Lachin, David Fitchett, Erich Bluhmki, Stefan Hantel, Michaela Mattheus, Theresa Devins, Odd Erik Johansen, Hans J Woerle,[...]. N Engl J Med 2015
69

Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction.
John J V McMurray, Scott D Solomon, Silvio E Inzucchi, Lars Køber, Mikhail N Kosiborod, Felipe A Martinez, Piotr Ponikowski, Marc S Sabatine, Inder S Anand, Jan Bělohlávek,[...]. N Engl J Med 2019
61

Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure.
Milton Packer, Stefan D Anker, Javed Butler, Gerasimos Filippatos, Stuart J Pocock, Peter Carson, James Januzzi, Subodh Verma, Hiroyuki Tsutsui, Martina Brueckmann,[...]. N Engl J Med 2020
986
53

Canagliflozin inhibits interleukin-1β-stimulated cytokine and chemokine secretion in vascular endothelial cells by AMP-activated protein kinase-dependent and -independent mechanisms.
Sarah J Mancini, Daria Boyd, Omar J Katwan, Anastasiya Strembitska, Tarek A Almabrouk, Simon Kennedy, Timothy M Palmer, Ian P Salt. Sci Rep 2018
104
46

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.
Stephen D Wiviott, Itamar Raz, Marc P Bonaca, Ofri Mosenzon, Eri T Kato, Avivit Cahn, Michael G Silverman, Thomas A Zelniker, Julia F Kuder, Sabina A Murphy,[...]. N Engl J Med 2019
46

Angiotensin II-induced redox-sensitive SGLT1 and 2 expression promotes high glucose-induced endothelial cell senescence.
Sonia Khemais-Benkhiat, Eugenia Belcastro, Noureddine Idris-Khodja, Sin-Hee Park, Lamia Amoura, Malak Abbas, Cyril Auger, Laurence Kessler, Eric Mayoux, Florence Toti,[...]. J Cell Mol Med 2020
38
46

Empagliflozin and Dapagliflozin Reduce ROS Generation and Restore NO Bioavailability in Tumor Necrosis Factor α-Stimulated Human Coronary Arterial Endothelial Cells.
Laween Uthman, Anna Homayr, Rio P Juni, Eva L Spin, Raphaela Kerindongo, Marleen Boomsma, Markus W Hollmann, Benedikt Preckel, Pieter Koolwijk, Victor W M van Hinsbergh,[...]. Cell Physiol Biochem 2019
57
38

Shift to Fatty Substrate Utilization in Response to Sodium-Glucose Cotransporter 2 Inhibition in Subjects Without Diabetes and Patients With Type 2 Diabetes.
Ele Ferrannini, Simona Baldi, Silvia Frascerra, Brenno Astiarraga, Tim Heise, Roberto Bizzotto, Andrea Mari, Thomas R Pieber, Elza Muscelli. Diabetes 2016
315
38

Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.
Vlado Perkovic, Meg J Jardine, Bruce Neal, Severine Bompoint, Hiddo J L Heerspink, David M Charytan, Robert Edwards, Rajiv Agarwal, George Bakris, Scott Bull,[...]. N Engl J Med 2019
38

Cardiac Microvascular Endothelial Enhancement of Cardiomyocyte Function Is Impaired by Inflammation and Restored by Empagliflozin.
Rio P Juni, Diederik W D Kuster, Max Goebel, Michiel Helmes, René J P Musters, Jolanda van der Velden, Pieter Koolwijk, Walter J Paulus, Victor W M van Hinsbergh. JACC Basic Transl Sci 2019
67
30

Canagliflozin exerts anti-inflammatory effects by inhibiting intracellular glucose metabolism and promoting autophagy in immune cells.
Chenke Xu, Wei Wang, Jin Zhong, Fan Lei, Naihan Xu, Yaou Zhang, Weidong Xie. Biochem Pharmacol 2018
69
30


Class effects of SGLT2 inhibitors in mouse cardiomyocytes and hearts: inhibition of Na+/H+ exchanger, lowering of cytosolic Na+ and vasodilation.
Laween Uthman, Antonius Baartscheer, Boris Bleijlevens, Cees A Schumacher, Jan W T Fiolet, Anneke Koeman, Milena Jancev, Markus W Hollmann, Nina C Weber, Ruben Coronel,[...]. Diabetologia 2018
227
30

Empagliflozin protects heart from inflammation and energy depletion via AMPK activation.
Chintan N Koyani, Ioanna Plastira, Harald Sourij, Seth Hallström, Albrecht Schmidt, Peter P Rainer, Heiko Bugger, Saša Frank, Ernst Malle, Dirk von Lewinski. Pharmacol Res 2020
31
30

Empagliflozin Blunts Worsening Cardiac Dysfunction Associated With Reduced NLRP3 (Nucleotide-Binding Domain-Like Receptor Protein 3) Inflammasome Activation in Heart Failure.
Nikole J Byrne, Nobutoshi Matsumura, Zaid H Maayah, Mourad Ferdaoussi, Shingo Takahara, Ahmed M Darwesh, Jody L Levasseur, James Won Suk Jahng, Dyonne Vos, Nirmal Parajuli,[...]. Circ Heart Fail 2020
62
30

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.
Bruce Neal, Vlado Perkovic, Kenneth W Mahaffey, Dick de Zeeuw, Greg Fulcher, Ngozi Erondu, Wayne Shaw, Gordon Law, Mehul Desai, David R Matthews. N Engl J Med 2017
30

Empagliflozin decreases myocardial cytoplasmic Na+ through inhibition of the cardiac Na+/H+ exchanger in rats and rabbits.
Antonius Baartscheer, Cees A Schumacher, Rob C I Wüst, Jan W T Fiolet, Ger J M Stienen, Ruben Coronel, Coert J Zuurbier. Diabetologia 2017
291
23


Effect of Empagliflozin on Left Ventricular Mass in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease: The EMPA-HEART CardioLink-6 Randomized Clinical Trial.
Subodh Verma, C David Mazer, Andrew T Yan, Tamique Mason, Vinay Garg, Hwee Teoh, Fei Zuo, Adrian Quan, Michael E Farkouh, David H Fitchett,[...]. Circulation 2019
200
23

Myocardial Microvascular Inflammatory Endothelial Activation in Heart Failure With Preserved Ejection Fraction.
Constantijn Franssen, Sophia Chen, Andreas Unger, H Ibrahim Korkmaz, Gilles W De Keulenaer, Carsten Tschöpe, Adelino F Leite-Moreira, René Musters, Hans W M Niessen, Wolfgang A Linke,[...]. JACC Heart Fail 2016
258
23

Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes.
George L Bakris, Rajiv Agarwal, Stefan D Anker, Bertram Pitt, Luis M Ruilope, Peter Rossing, Peter Kolkhof, Christina Nowack, Patrick Schloemer, Amer Joseph,[...]. N Engl J Med 2020
294
23

Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure.
Deepak L Bhatt, Michael Szarek, P Gabriel Steg, Christopher P Cannon, Lawrence A Leiter, Darren K McGuire, Julia B Lewis, Matthew C Riddle, Adriaan A Voors, Marco Metra,[...]. N Engl J Med 2021
373
23

Anti-Inflammatory Effect for Atherosclerosis Progression by Sodium-Glucose Cotransporter 2 (SGLT-2) Inhibitor in a Normoglycemic Rabbit Model.
Seul Gee Lee, Seung Jun Lee, Jung Jae Lee, Jung Sun Kim, Oh Hyun Lee, Choong Ki Kim, Darae Kim, Yong Ho Lee, Jaewon Oh, Seil Park,[...]. Korean Circ J 2020
15
23


Empagliflozin rescues diabetic myocardial microvascular injury via AMPK-mediated inhibition of mitochondrial fission.
Hao Zhou, Shuyi Wang, Pingjun Zhu, Shunying Hu, Yundai Chen, Jun Ren. Redox Biol 2018
231
23

SGLT inhibitors attenuate NO-dependent vascular relaxation in the pulmonary artery but not in the coronary artery.
Ying Han, Young-Eun Cho, Ramon Ayon, Rui Guo, Katia D Youssef, Minglin Pan, Anzhi Dai, Jason X-J Yuan, Ayako Makino. Am J Physiol Lung Cell Mol Physiol 2015
57
23

Empagliflozin restores chronic kidney disease-induced impairment of endothelial regulation of cardiomyocyte relaxation and contraction.
Rio P Juni, Rushd Al-Shama, Diederik W D Kuster, Jolanda van der Velden, Henrike M Hamer, Marc G Vervloet, Etto C Eringa, Pieter Koolwijk, Victor W M van Hinsbergh. Kidney Int 2021
12
25

SGLT2 inhibition modulates NLRP3 inflammasome activity via ketones and insulin in diabetes with cardiovascular disease.
So Ra Kim, Sang-Guk Lee, Soo Hyun Kim, Jin Hee Kim, Eunhye Choi, Wonhee Cho, John Hoon Rim, Inhwa Hwang, Chan Joo Lee, Minyoung Lee,[...]. Nat Commun 2020
89
23


Dapagliflozin attenuates human vascular endothelial cell activation and induces vasorelaxation: A potential mechanism for inhibition of atherogenesis.
Tracey Gaspari, Iressa Spizzo, HongBin Liu, Yunshan Hu, Richard W Simpson, Robert E Widdop, Anthony E Dear. Diab Vasc Dis Res 2018
36
23

The SGLT2 Inhibitor Luseogliflozin Rapidly Normalizes Aortic mRNA Levels of Inflammation-Related but Not Lipid-Metabolism-Related Genes and Suppresses Atherosclerosis in Diabetic ApoE KO Mice.
Yusuke Nakatsu, Hiroki Kokubo, Batmunkh Bumdelger, Masao Yoshizumi, Takeshi Yamamotoya, Yasuka Matsunaga, Koji Ueda, Yuki Inoue, Masa-Ki Inoue, Midori Fujishiro,[...]. Int J Mol Sci 2017
40
23

SGLT-2 (Sodium-Glucose Cotransporter 2) Inhibition Reduces Ang II (Angiotensin II)-Induced Dissecting Abdominal Aortic Aneurysm in ApoE (Apolipoprotein E) Knockout Mice.
Rebeca Ortega, Aida Collado, Francisca Selles, Herminia Gonzalez-Navarro, Maria-Jesus Sanz, José T Real, Laura Piqueras. Arterioscler Thromb Vasc Biol 2019
31
23

Glycemic Control with Ipragliflozin, a Novel Selective SGLT2 Inhibitor, Ameliorated Endothelial Dysfunction in Streptozotocin-Induced Diabetic Mouse.
Hotimah Masdan Salim, Daiju Fukuda, Shusuke Yagi, Takeshi Soeki, Michio Shimabukuro, Masataka Sata. Front Cardiovasc Med 2016
62
23

Empagliflozin ameliorates endothelial dysfunction and suppresses atherogenesis in diabetic apolipoprotein E-deficient mice.
Byambasuren Ganbaatar, Daiju Fukuda, Masakazu Shinohara, Shusuke Yagi, Kenya Kusunose, Hirotsugu Yamada, Takeshi Soeki, Ken-Ichi Hirata, Masataka Sata. Eur J Pharmacol 2020
33
23

Hyperglycaemic impairment of PAR2-mediated vasodilation: Prevention by inhibition of aortic endothelial sodium-glucose-co-Transporter-2 and minimizing oxidative stress.
Mahmoud El-Daly, Vivek Krishna Pulakazhi Venu, Mahmoud Saifeddine, Koichiro Mihara, Sean Kang, Paul W M Fedak, Laurie A Alston, Simon A Hirota, Hong Ding, Chris R Triggle,[...]. Vascul Pharmacol 2018
53
23

The SGLT2 inhibitor Empagliflozin attenuates interleukin-17A-induced human aortic smooth muscle cell proliferation and migration by targeting TRAF3IP2/ROS/NLRP3/Caspase-1-dependent IL-1β and IL-18 secretion.
Sergiy Sukhanov, Yusuke Higashi, Tadashi Yoshida, Srinivas Mummidi, Annayya R Aroor, Jacob Jeffrey Russell, Shawn B Bender, Vincent G DeMarco, Bysani Chandrasekar. Cell Signal 2021
15
23

The SGLT-2 Inhibitor Dapagliflozin Has a Therapeutic Effect on Atherosclerosis in Diabetic ApoE-/- Mice.
Weiling Leng, Xinshou Ouyang, Xiaotian Lei, Mingxia Wu, Liu Chen, Qinan Wu, Wuquan Deng, Ziwen Liang. Mediators Inflamm 2016
80
23

Canagliflozin Prevents Diabetes-Induced Vascular Dysfunction in ApoE-Deficient Mice.
Arief Rahadian, Daiju Fukuda, Hotimah Masdan Salim, Shusuke Yagi, Kenya Kusunose, Hirotsugu Yamada, Takeshi Soeki, Masataka Sata. J Atheroscler Thromb 2020
22
23

Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes.
Christopher P Cannon, Richard Pratley, Samuel Dagogo-Jack, James Mancuso, Susan Huyck, Urszula Masiukiewicz, Bernard Charbonnel, Robert Frederich, Silvina Gallo, Francesco Cosentino,[...]. N Engl J Med 2020
378
23

Empagliflozin Increases Cardiac Energy Production in Diabetes: Novel Translational Insights Into the Heart Failure Benefits of SGLT2 Inhibitors.
Subodh Verma, Sonia Rawat, Kim L Ho, Cory S Wagg, Liyan Zhang, Hwee Teoh, John E Dyck, Golam M Uddin, Gavin Y Oudit, Eric Mayoux,[...]. JACC Basic Transl Sci 2018
158
23

Anti-inflammatory effects of sodium-glucose co-transporter 2 inhibitors on atherosclerosis.
Yingxiu Kang, Fenfen Zhan, Minzhi He, Zhenjie Liu, Xiaoxiao Song. Vascul Pharmacol 2020
11
27

The SGLT2 inhibitor empagliflozin improves the primary diabetic complications in ZDF rats.
Sebastian Steven, Matthias Oelze, Alina Hanf, Swenja Kröller-Schön, Fatemeh Kashani, Siyer Roohani, Philipp Welschof, Maximilian Kopp, Ute Gödtel-Armbrust, Ning Xia,[...]. Redox Biol 2017
123
23

Empagliflozin improved systolic blood pressure, endothelial dysfunction and heart remodeling in the metabolic syndrome ZSF1 rat.
Sin-Hee Park, Muhammad Akmal Farooq, Sébastien Gaertner, Christophe Bruckert, Abdul Wahid Qureshi, Hyun-Ho Lee, Djamel Benrahla, Brigitte Pollet, Dominique Stephan, Patrick Ohlmann,[...]. Cardiovasc Diabetol 2020
33
23

The SGLT2 inhibitor empagliflozin reduces mortality and prevents progression in experimental pulmonary hypertension.
Biswajit Chowdhury, Albert Z Luu, Vincent Z Luu, M Golam Kabir, Yi Pan, Hwee Teoh, Adrian Quan, Sandra Sabongui, Mohammed Al-Omran, Deepak L Bhatt,[...]. Biochem Biophys Res Commun 2020
29
23

Dapagliflozin in Patients with Chronic Kidney Disease.
Hiddo J L Heerspink, Bergur V Stefánsson, Ricardo Correa-Rotter, Glenn M Chertow, Tom Greene, Fan-Fan Hou, Johannes F E Mann, John J V McMurray, Magnus Lindberg, Peter Rossing,[...]. N Engl J Med 2020
786
23

Angiotensin II-induced upregulation of SGLT1 and 2 contributes to human microparticle-stimulated endothelial senescence and dysfunction: protective effect of gliflozins.
Sin-Hee Park, Eugenia Belcastro, Hira Hasan, Kensuke Matsushita, Benjamin Marchandot, Malak Abbas, Florence Toti, Cyril Auger, Laurence Jesel, Patrick Ohlmann,[...]. Cardiovasc Diabetol 2021
12
25

Empagliflozin improves endothelial and cardiomyocyte function in human heart failure with preserved ejection fraction via reduced pro-inflammatory-oxidative pathways and protein kinase Gα oxidation.
Detmar Kolijn, Steffen Pabel, Yanna Tian, Mária Lódi, Melissa Herwig, Albino Carrizzo, Saltanat Zhazykbayeva, Árpád Kovács, Gábor Á Fülöp, Inês Falcão-Pires,[...]. Cardiovasc Res 2021
50
23

Empagliflozin in Heart Failure with a Preserved Ejection Fraction.
Stefan D Anker, Javed Butler, Gerasimos Filippatos, João P Ferreira, Edimar Bocchi, Michael Böhm, Hans-Peter Brunner-La Rocca, Dong-Ju Choi, Vijay Chopra, Eduardo Chuquiure-Valenzuela,[...]. N Engl J Med 2021
266
23


Glutamine fuels proliferation but not migration of endothelial cells.
Boa Kim, Jia Li, Cholsoon Jang, Zoltan Arany. EMBO J 2017
106
15


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.